Ayana T. Ruffin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ayana T. Ruffin has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Chrystal M. Paulos
Winship Cancer Institute, Emory University
68 shared publications - Gregory B. Lesinski
Emory University
67 shared publications - Alyssa M. Krasinskas
Department of Pathology, Emory University, Atlanta, USA
41 shared publications - Bassel F. El-Rayes
Division of Hematology and Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
41 shared publications - Cameron J. Herting
Emory University 1 Department of Hematology and Medical Oncology Atlanta, Georgia
41 shared publications - Deon Bryant Doxie
Winship Cancer Institute of Emory University, Atlanta, USA
41 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Springer Nature in Research Square
PolarTIL programming reveals an essential role for TGF-β1 in antitumor memory in human cutaneous malignancies
Tumor-infiltrating lymphocyte (TIL) therapy can induce tumor regression in solid malignancies, yet durable responses remain limited, highlighting the need for more effective cell products. Here, we generated a novel TIL product, PolarTIL, by polarizing murine and human TIL from cutaneous malignancies ex vivo with a defined Type-17 cytokine cocktail. Compared with conventional IL-2 culture, PolarTIL produced greater cell yields and a distinct cellular state marked by reduced CD4⁺ regulatory T cells, enrichment of CD103⁺ populations, and superior antitumor activity in vitro and in vivo . Unexpectedly, TGF-β1 emerged as a critical regulator of PolarTIL function. Although TGF-β is commonly targeted for inhibition in cancer immunotherapy, its removal during PolarTIL generation completely abolished therapeutic efficacy in vivo . Together, these findings reveal an unrecognized requirement for TGF-β1 in programming effective TIL responses and establish PolarTIL as a promising next-generation cellular therapy for solid tumors.
- 30 October 2026
- Published by Springer Nature in Research Square
Open AccessPolarTIL programming reveals an essential role for TGF-β1 in antitumor memory in human cutaneous malignancies
Tumor-infiltrating lymphocyte (TIL) therapy can induce tumor regression in solid malignancies, yet durable responses remain limited, highlighting the need for more effective cell products. Here, we generated a novel TIL product, PolarTIL, by polarizing murine and human TIL from cutaneous malignancies ex vivo with a defined Type-17 cytokine cocktail. Compared with conventional IL-2 culture, PolarTIL produced greater cell yields and a distinct cellular state marked by reduced CD4⁺ regulatory T cells, enrichment of CD103⁺ populations, and superior antitumor activity in vitro and in vivo . Unexpectedly, TGF-β1 emerged as a critical regulator of PolarTIL function. Although TGF-β is commonly targeted for inhibition in cancer immunotherapy, its removal during PolarTIL generation completely abolished therapeutic efficacy in vivo . Together, these findings reveal an unrecognized requirement for TGF-β1 in programming effective TIL responses and establish PolarTIL as a promising next-generation cellular therapy for solid tumors.
- Open Access
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial
Neoadjuvant immune checkpoint inhibitors (ICIs) improve event-free survival in metastatic melanoma, yet resistance and recurrence remain common. Here we evaluated pepinemab, a Semaphorin 4D (SEMA4D)–blocking antibody, in combination with anti-PD1 nivolumab and/or anti-CTLA4 ipilimumab in a pilot biomarker-driven neoadjuvant trial (NCT03769155) for patients with resectable metastatic melanoma. The primary endpoint was to determine if pepinemab combined with ICIs modulates phenotypic properties within the tumor microenvironment in a manner that enhances T effector cell infiltration. Secondary endpoints included safety and tolerability, pathological response rates and radiographical response. Patients received two neoadjuvant doses followed by curative-intent surgery and one year of adjuvant nivolumab. Pepinemab-containing regimens demonstrated manageable toxicity profiles and did not delay or preclude curative-intent surgical resection in the 38 patients treated. The trial met its primary endpoint, as enrichment of transcripts associated with activated dendritic cells and immune recruitment pathways was observed in tumors from patients receiving pepinemab-containing regimens. Further, immune remodeling was evident by formation of mature lymphoid aggregates resembling tertiary lymphoid structures that contained clonally expanded T cell receptor repertoires. While this study was not powered to assess clinical efficacy, our findings do support further evaluation of SEMA4D blockade as a strategy to modulate the tumor microenvironment and potentially augment immunotherapy in melanoma and other solid malignancies.
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessNeoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial
Neoadjuvant immune checkpoint inhibitors (ICIs) improve event-free survival in metastatic melanoma, yet resistance and recurrence remain common. Here we evaluated pepinemab, a Semaphorin 4D (SEMA4D)–blocking antibody, in combination with anti-PD1 nivolumab and/or anti-CTLA4 ipilimumab in a pilot biomarker-driven neoadjuvant trial (NCT03769155) for patients with resectable metastatic melanoma. The primary endpoint was to determine if pepinemab combined with ICIs modulates phenotypic properties within the tumor microenvironment in a manner that enhances T effector cell infiltration. Secondary endpoints included safety and tolerability, pathological response rates and radiographical response. Patients received two neoadjuvant doses followed by curative-intent surgery and one year of adjuvant nivolumab. Pepinemab-containing regimens demonstrated manageable toxicity profiles and did not delay or preclude curative-intent surgical resection in the 38 patients treated. The trial met its primary endpoint, as enrichment of transcripts associated with activated dendritic cells and immune recruitment pathways was observed in tumors from patients receiving pepinemab-containing regimens. Further, immune remodeling was evident by formation of mature lymphoid aggregates resembling tertiary lymphoid structures that contained clonally expanded T cell receptor repertoires. While this study was not powered to assess clinical efficacy, our findings do support further evaluation of SEMA4D blockade as a strategy to modulate the tumor microenvironment and potentially augment immunotherapy in melanoma and other solid malignancies.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Data from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the benefits of TLR agonists. In this study, we identified an innate–adaptive circuit in which TLR9-activated B cells augment CD8+ T-cell fitness and antitumor activity through CD2-dependent costimulation. Among multiple TLR agonists tested, class B CpG uniquely programmed murine and human CD8+ T cells for superior effector differentiation, metabolic fitness, and antitumor control. Disruption of CD2 signaling blunted the benefits of TLR9 agonism, including impaired glycolytic capacity and reduced tumor control. Independently, blocking other costimulatory molecules, such as CD86, CD80, CD28, or inducible T-cell costimulator (ICOS), did not impair the antitumor activity of CpG-conditioned T cells. Gain-of-function experiments revealed that CD2 stimulation recapitulated the effect of TLR9 agonism, bolstering the effector function of tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells. Consistent with these findings, elevated CD2 expression in human tumors correlated with improved overall survival across multiple patient cohorts with cancer, underscoring the clinical importance of this signaling cue. Together, these data uncover a noncanonical B-cell–CD2 costimulation axis through which TLR9 agonists potentiate ACT, revealing a targetable pathway to overcome resistance to cell therapy in solid tumors. Significance:B cells activated with TLR9 agonist cross-talk with CD8+ T cells via CD2, which enhances their fitness, cytotoxic function, and antitumor activity against solid tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the benefits of TLR agonists. In this study, we identified an innate–adaptive circuit in which TLR9-activated B cells augment CD8+ T-cell fitness and antitumor activity through CD2-dependent costimulation. Among multiple TLR agonists tested, class B CpG uniquely programmed murine and human CD8+ T cells for superior effector differentiation, metabolic fitness, and antitumor control. Disruption of CD2 signaling blunted the benefits of TLR9 agonism, including impaired glycolytic capacity and reduced tumor control. Independently, blocking other costimulatory molecules, such as CD86, CD80, CD28, or inducible T-cell costimulator (ICOS), did not impair the antitumor activity of CpG-conditioned T cells. Gain-of-function experiments revealed that CD2 stimulation recapitulated the effect of TLR9 agonism, bolstering the effector function of tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells. Consistent with these findings, elevated CD2 expression in human tumors correlated with improved overall survival across multiple patient cohorts with cancer, underscoring the clinical importance of this signaling cue. Together, these data uncover a noncanonical B-cell–CD2 costimulation axis through which TLR9 agonists potentiate ACT, revealing a targetable pathway to overcome resistance to cell therapy in solid tumors. Significance:B cells activated with TLR9 agonist cross-talk with CD8+ T cells via CD2, which enhances their fitness, cytotoxic function, and antitumor activity against solid tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CpG conditioning by distinct CpG classes on pmel-1 CD8 increases T cell activation and cytokine production
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CpG conditioning by distinct CpG classes on pmel-1 CD8 increases T cell activation and cytokine production
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD28 or Icos blocking does not impair CpG conditioned CD8 T cells
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD28 or Icos blocking does not impair CpG conditioned CD8 T cells
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 signaling is required for TLR9 driven B cell differentiation
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 signaling is required for TLR9 driven B cell differentiation
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Metabolic profiling of B cells and CD8 T cells following CpG conditioning and CD2 blockade
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Metabolic profiling of B cells and CD8 T cells following CpG conditioning and CD2 blockade
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Flow cytometry and blocking antibody list
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Flow cytometry and blocking antibody list
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
TLR9-activated B cell interactions with human CD8 T cells may limit their exhaustion
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
TLR9-activated B cell interactions with human CD8 T cells may limit their exhaustion
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 and CD58 expression is increased in intratumoral human B and T cells
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 and CD58 expression is increased in intratumoral human B and T cells